



FOR IMMEDIATE RELEASE

The Caris Precision Oncology Alliance Welcomes The Broad Institute of MIT and Harvard

The Broad Institute joins Caris' extensive network of leading cancer institutions and research consortia committed to improving patient outcomes through innovations in precision medicine

IRVING, Texas, July 13, 2023 – [Caris Life Sciences](#)[®] (Caris), the leading molecular science and technology company actively developing and delivering innovative solutions to revolutionize healthcare, announced today that the Broad Institute of MIT and Harvard has joined the [Caris Precision Oncology Alliance](#)[™] (POA). As a POA member, the Broad Institute will collaborate with Caris on various precision oncology research projects and signature development.

The POA is a growing network of leading cancer centers and research consortia across the globe that collaborate to advance precision oncology and biomarker-driven research, with its members working together to establish and optimize standards of care for molecular testing through innovative research to improve clinical outcomes for cancer patients. POA members are uniquely positioned to leverage Caris' highly sophisticated AI bioinformatics and machine learning capabilities across the company's massive clinico-genomic database to enable innovative research to improve clinical outcomes for cancer patients.

The Broad Institute of MIT and Harvard is an independent, nonprofit research organization that convenes a community of researchers from across many disciplines from the MIT, Harvard, and Harvard-affiliated hospital community.

"We're thrilled to welcome the Broad Institute to the Caris POA. Their inclusion in Caris' extensive network is a further testament to our commitment to precision oncology research through collaboration with institutions executing on cutting edge ideas," said [David Dean Halbert](#), DSc (h.c.), Chairman, Founder and CEO of Caris. "The Caris POA and the Broad Institute share a vision of improving the outcomes of all patients affected with cancer."

The Caris Precision Oncology Alliance includes 86 cancer centers, academic institutions, research consortia and healthcare systems. These institutions have early access to the extensive database and artificial intelligence platform within Caris to establish evidence-based standards for cancer profiling and molecular testing in oncology. By leveraging the comprehensive genomic, transcriptomic and proteomic profiling available through Caris molecular profiling, Caris seeks to provide this network with the ability to prioritize therapeutic options and determine which clinical trial opportunities may benefit their patients. POA members are also able to integrate with a growing portfolio of biomarker-directed trials sponsored by biopharma. Additionally, POA member institutions have access to the most comprehensive clinico-genomic database in the

industry, which includes matched molecular and clinical outcomes data from hundreds of thousands of cancer patients, covering over 1 million data points per patient.

About Caris Life Sciences

Caris Life Sciences® (Caris) is the pioneer in precision medicine and leading molecular science and technology company actively developing and delivering innovative solutions to revolutionize healthcare and improve patient outcomes. Through comprehensive molecular profiling (Whole Exome and Whole Transcriptome Sequencing) and the application of advanced artificial intelligence (AI) and machine learning algorithms, Caris has created the large-scale clinico-genomic database and cognitive computing needed to analyze and unravel the molecular complexity of disease. This convergence of data and machine learning provides an unmatched resource and the ideal path forward to conduct the basic, fundamental research to accelerate discovery for detection, diagnosis, monitoring, therapy selection and drug development to improve the human condition.

With a primary focus on cancer, Caris' suite of market-leading molecular profiling offerings assesses DNA, RNA and proteins to reveal a molecular blueprint that helps patients, physicians and researchers better detect, diagnose and treat patients. The company's latest advancement, [Caris Assure™](#), is a blood-based, circulating nucleic acids sequencing (cNAS) assay that combines comprehensive molecular analysis (Whole Exome and Whole Transcriptome Sequencing from blood) and serial monitoring – making it the most powerful liquid biopsy assay ever developed.

Headquartered in Irving, Texas, Caris has offices in Phoenix, New York, Tokyo, Japan and Basel, Switzerland. Caris or its distributors provide services in the U.S., Europe, Asia and other international markets. To learn more, please visit CarisLifeSciences.com or follow us on [LinkedIn](#).

###

Caris Life Sciences Media Contact:

Lisa Burgner
214.294.5606